Dec 2, 2024
Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550
Feb 13, 2024
Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
Dec 20, 2023
Sudo Biosciences Raises $116M Series B Financing to Advance Potential Best-in-Class TYK2 Therapeutics Programs into the Clinic
Oct 10, 2022
Sudo Biosciences Appoints Imran Babar, Ph.D., as Chief Business Officer
Sept 28, 2022
Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics
Back to News
